Renal Cancer - Results from #540

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. January 18, 2024

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma. January 18, 2024

Immuno-Oncology Advances in Genitourinary Cancers. January 17, 2024

Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. January 17, 2024

Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma. January 17, 2024

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. January 16, 2024

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. January 16, 2024

Update on Biomarkers in Renal Cell Carcinoma. January 15, 2024

Robotic Radical Nephrectomy with Vena Cava Thrombus Extraction (RRN-VCTE) for Renal Cell Carcinoma: A Meta-Analysis of Surgical Technique and Outcomes. January 15, 2024

Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma. January 15, 2024

Anemia in patients ≥ 75 years with metastatic clear cell renal cell carcinoma: an important poor prognostic factor in the international metastatic renal cell carcinoma database consortium model. January 15, 2024

Renal functional outcomes after robot-assisted partial nephrectomy and percutaneous cryoablation of clinical T1 renal cell carcinoma - A prospective study. January 12, 2024

Role of Renal Biopsy in the Management of Renal Cancer: Concordance between Ultrasound/CT-Guided Biopsy Results and Definitive Pathology, Adverse Events, and Complication Rate. January 12, 2024

Evolution of cell therapy for renal cell carcinoma. January 11, 2024

CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma. January 11, 2024

Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy. January 10, 2024

Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy. January 10, 2024

Understanding Factors that Influence Prognosis and Response to Therapy in Clear Cell Renal Cell Carcinoma. January 9, 2024

Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). January 9, 2024

AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Advanced Renal Cell Carcinoma January 8, 2024

Page 28 of 456